CN118401239A - 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮 - Google Patents

用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮 Download PDF

Info

Publication number
CN118401239A
CN118401239A CN202280070003.5A CN202280070003A CN118401239A CN 118401239 A CN118401239 A CN 118401239A CN 202280070003 A CN202280070003 A CN 202280070003A CN 118401239 A CN118401239 A CN 118401239A
Authority
CN
China
Prior art keywords
fdck
administered
depression
amount
antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280070003.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·戈兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Climax Labs Inc
Original Assignee
Kelimai Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kelimai Pharmaceutical Co filed Critical Kelimai Pharmaceutical Co
Publication of CN118401239A publication Critical patent/CN118401239A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280070003.5A 2021-10-18 2022-10-18 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮 Pending CN118401239A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256728P 2021-10-18 2021-10-18
US63/256728 2021-10-18
PCT/IB2022/060011 WO2023067505A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publications (1)

Publication Number Publication Date
CN118401239A true CN118401239A (zh) 2024-07-26

Family

ID=84178934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280070003.5A Pending CN118401239A (zh) 2021-10-18 2022-10-18 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮

Country Status (8)

Country Link
US (1) US20250032429A1 (https=)
EP (1) EP4419092A1 (https=)
JP (1) JP2024538015A (https=)
KR (1) KR20240093579A (https=)
CN (1) CN118401239A (https=)
AU (1) AU2022374097A1 (https=)
CA (1) CA3233107A1 (https=)
WO (1) WO2023067505A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094757A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途

Also Published As

Publication number Publication date
US20250032429A1 (en) 2025-01-30
EP4419092A1 (en) 2024-08-28
CA3233107A1 (en) 2023-04-27
WO2023067505A1 (en) 2023-04-27
AU2022374097A1 (en) 2024-03-14
JP2024538015A (ja) 2024-10-18
KR20240093579A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
US20250032432A1 (en) Bupropion as a modulator of drug activity
US11433067B2 (en) Bupropion as a modulator of drug activity
US11207281B2 (en) Bupropion as a modulator of drug activity
US11273134B2 (en) Bupropion as a modulator of drug activity
US10898453B2 (en) Bupropion as a modulator of drug activity
US11147808B2 (en) Method of decreasing the fluctuation index of dextromethorphan
US10945973B2 (en) Bupropion as a modulator of drug activity
US11213521B2 (en) Bupropion as a modulator of drug activity
US11123343B2 (en) Bupropion as a modulator of drug activity
US10966974B2 (en) Bupropion as a modulator of drug activity
US10772850B2 (en) Bupropion as a modulator of drug activity
US10874665B2 (en) Bupropion as a modulator of drug activity
CN112437659B (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
US20220008363A1 (en) Bupropion as a modulator of drug activity
US20210069125A1 (en) Bupropion as a modulator of drug activity
US20210030747A1 (en) Bupropion as a modulator of drug activity
US20210077429A1 (en) Bupropion as a modulator of drug activity
JP2025032232A (ja) アルツハイマー病に関連する焦燥を治療するための医薬
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
JP2007526335A (ja) 焦燥およびその他の行動障害、特にアルツハイマー病に関連する行動障害の治療用１−アミノシクロヘキサン誘導体
CN118401239A (zh) 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
JP2025504069A (ja) オキシトシンを使用した治療方法
HK40074123A (en) Combination of dextromethorphan and bupropion for treating depression
HK40074121A (en) Combination of dextromethorphan and bupropion for treating depression
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260128

Address after: British Columbia

Applicant after: Climax Labs Inc.

Country or region after: Canada

Address before: Israel Tel Aviv

Applicant before: Kelimai Pharmaceutical Co.

Country or region before: Canada